CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-16). The draft was written by AI, the existence of all 3 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 379 · Search date 2026-07-16 · Methodology v0.6

Caper bush root,
does it really help with Hepatocyte protection and liver detoxification?

30-Second Summary
?
Evidence Grade ? · Safety unknown
Results for the Liv.52 combination cannot be transferred to standalone caper bush root
What the
research shows
The verdict is unknown because no standalone human liver-efficacy trial of caper bush root was identified. Liv.52 and LiverCare combine caper with several herbs and mineral ingredients, so results from trials or meta-analyses of the combination cannot be attributed to caper root alone.
What the
ads claim
The long marketing history, product name, and liver studies of a combination are used as if every listed herb independently regenerates hepatocytes or removes toxins.
*

Useful facts when choosing a product

  • In Korea, imported Liv.52 or LiverCare combinations are more visible than standalone caper-root products.
  • The herbal composition and amounts in Liv.52 products can vary by version, country, and tablet specification.
  • There is no validated standalone caper-root research dose for liver efficacy.
  • People with liver disease should not replace prescribed treatment with a multi-herb product and should assess formulation-specific interactions and quality separately.
Gap Measurement · Verdict 379 · ?
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

A 36-person cirrhosis trial and a 2025 meta-analysis of ten trials with 758 participants evaluated the entire multi-ingredient Liv.52 formula and could not isolate caper-root contribution. A separate 54-person diabetes trial tested caper fruit extract, so it cannot be attributed to the root or to hepatocyte protection and detoxification. Liv.52 papers are therefore cited only as indirect evidence of non-attributability, not as standalone caper-root efficacy citations.

02

Why this is classified as ?

Combination trials were excluded from standalone attribution. With no human efficacy literature for caper root alone, the grade is unknown and the score is null.

Counterpoint. Liv.52 itself is a separate product-level question and must not be conflated with an ingredient-level verdict.

Rejudgment record. Reassessment (cross-check reflected) — Liv.52 combination results and unrelated caper-fruit results cannot be attributed to the root, and no standalone human liver-efficacy trial of caper bush root was identified

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Liv.52 cirrhosis trial (2005)Randomized double-blind placebo-controlled trial36UnknownChild-Pugh score, ascites, and liver enzymesSelected combination outcomes were favorable; standalone caper-root contribution cannot be isolatedExcluded from standalone attribution
Priya et al. (2025)Systematic review and meta-analysis of Liv.52758Academic and public-institution investigatorsLiver enzymes, symptoms, and fat metabolismSelected signals but many liver-enzyme outcomes were null; evidence quality was low or very lowIndirect combination evidence, excluded from standalone attribution
Huseini et al. (2013)Randomized double-blind placebo-controlled diabetes trial54Academic researchFasting glucose, glycated hemoglobin, and lipidsTested caper fruit extract and cannot establish root or liver efficacyIndirect, different plant part and indication
§

Receipt — 3 References

All 3 cited sources were verified for existence at the original page (as of 2026-07-16).

Huseini HF, Alavian SM, Heshmat R, Heydari MR, Abolmaali K. The efficacy of Liv-52 on liver cirrhotic patients: a randomized, double-blind, placebo-controlled first approach. Phytomedicine. 2005;12(9):619-624. PMID: 16194047. DOI: 10.1016/j.phymed.2004.10.003.
checked
Priya A, Kumari M, Kumar A, et al. Effect of LIV-52 for the Treatment of Hepatic Disorders: A Systematic Review and Meta-Analysis. J Integr Complement Med. 2025;31(12):1021-1030. PMID: 40601500. DOI: 10.1089/jicm.2024.0703.
checked
Huseini HF, Hasani-Rnjbar S, Nayebi N, et al. Capparis spinosa L. (Caper) fruit extract in treatment of type 2 diabetic patients: a randomized double-blind placebo-controlled clinical trial. Complement Ther Med. 2013;21(5):447-452. DOI: 10.1016/j.ctim.2013.07.003.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-16 · Corrections: none

Cite this verdict

Caper bush root x hepatocyte protection and liver detoxification Evidence Grade ? card
[Chamgap] Caper bush root x hepatocyte protection and liver detoxification — Evidence Grade ?. 3 cited sources checked. Source: https://chamgap.com/en/verdicts/liver/caper-bush-root-liver-protection-detox/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.